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The aortic valve (AV) can be commonly affectedin children by several disease pathologies,
frequently necessitating intervention [1,2]. The
etiology of AV disease varies in different social
and geographic locations; while congenital heart
disease (CHD) is the most frequent pathology in
Europe and North America, rheumatic fever (RF)
remains a major pathology in developing coun-
tries [2]. Other less common pathologies include
endocarditis, trauma and degenerative disorders.
Several developments in interventional cardiol-
ogy allowed for early treatment of congenital aor-
tic stenosis (AS), and recent experience with AV
repair techniques demonstrated encouraging
short-term and mid-term results in both congeni-
tal and rheumatic AV disease [3–6]. Current evi-
dence supports AV repair as an initial palliative
or lasting intervention in children with AV disease
[3–6]. Nonetheless, in patients with significant
valve destruction and after repair or intervention
failure, AV replacement (AVR) is necessary [1,2].
AVR in children is associated with distinct clinical
and technical problems owing to several ana-
tomic, social and prosthesis-related issues.
In the current review, we list different AV
substitutes, discuss their advantages and short-
comings, outline AVR results in children, and
explore the divergence of outcomes in various
age, anatomy and pathology subgroups; all in
the aim to identify optimal AVR choice for each
patient taking into consideration his unique ana-
tomic and demographic characteristics.Available valve substitutes
Optimal AV substitute in children would be one
that’s readily available in different sizes, associ-
ated with excellent durable hemodynamic profile,
has growth potential proportional to somatic
enlargement, non-immunogenic, associated with
minimal thrombo-embolism (TE) risk thus not
requiring anticoagulation, and finally associated
with excellent prosthesis longevity and low inci-
dence of structural valve degeneration (SVD). No
such choice is currently available to surgeons’ dis-
posal and all valve alternatives are associated with
important limitations.
Mechanical prostheses (MP)
MPs are readily available and come in different
ranges with some small sizes (16 and 18 mm) suit-
able for young patients. Nonetheless, they’re still
not suitable for infants and very small childrenwho would require very small size prostheses that
are not currently available at surgeons’ disposal.
Their hemodynamic profiles vary with size and
smaller prostheses have inferior flow properties.
Special annular enlargement techniques could
be utilized to allow placement of a larger prosthe-
sis that could help with faster regression of left
ventricular (LV) hypertrophy, improved LV func-
tion and improved symptoms. Those techniques
include the Nicks procedure: aortic incision is ex-
tended to the area between the left/non coronary
commissure and the base of the noncoronary cusp
into the area of intervalvular fibrosa without cut-
ting into the anterior mitral valve (MV) leaflet
[7]; the Manougian procedure: almost same inci-
sion as in Nicks procedure but the cut is extended
across the intervalvular fibrosa into the center of
the anterior MV leaflet [8]; or the Konno proce-
dure: the aortic annulus is incised between the
right and left coronary cusps extending into the
ventricular septum with patch reconstruction of
the septum and ascending aorta [9].
Reported operative mortality of AVR with MP in
children is 2–13% [1,10–14]; risk factors include
younger age, presence of LV dysfunction and con-
comitant cardiac anomalies requiring surgery.
Moreover, those children continue to have con-
stant attrition rate with 15-year survival of 75–
88% [1,10–14].
Most importantly, MPs require life-long antico-
agulation to prevent TE. Anticoagulation in chil-
dren can be challenging due to lack of
compliance with medication and activity restraints
therefore children could theoretically be at a high-
er risk of TE and anticoagulation-related bleeding
complications. Nevertheless, despite those chal-
lenges, it seems that children are at lower risk of
TE and bleeding than adults. In the literature, at
follow-up ranging between 10 and 20 years, re-
ported freedom from TE is 90–100% with average
linearized rate of 0.3–0.7 per 100 patient-years
and reported freedom from bleeding is 96% to
100% with average linearized rate of 0.3 per 100
patient-years [10–15]. It might be that children
have different hemodynamic properties than
adults with faster heart rate, less incidence of
arrhythmias, atrial dilatation or myocardial dys-
function; all making them less prone to develop
TE than adults. Those findings should be inter-
preted with caution given the fact that there is a
continuous attrition risk in children who had
received MPs with many late deaths sudden in
nature, likely due to under-reported TE incidents.
Despite the lack of SVD, reoperations following
AVR with MP in children are not uncommon
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15 years [1,2,10–14]. Reoperations are usually
related to development of patient-prosthesis
mismatch (PPM) as the child grows older in the
presence of fixed MP sizes that lack growth poten-
tial. Reoperations are also often indicated for
pannus formation creating subvalvular obstruc-
tion, a complication that’s likely more common
in children than in adults; in addition to few
reported reoperations for valve thrombosis,
paravalvular leak or endocarditis [1,2,10–14].
Nevertheless, considering other available AVR
options, MPs continue to offer some of the highest
reported freedom from reoperation rates.Tissue prostheses (TP)
TPs are readily available and come in different
ranges however they’re unavailable in sizes smal-
ler than 19 mm, and hence are not suitable for
small children even if annular enlargement tech-
niques were utilized. Similar to MPs, their hemo-
dynamic profiles vary with size and smaller
prostheses have inferior flow properties.
TPs have a very low risk of TE and therefore do
not require life-long anticoagulation. Nonethe-
less, their use in pediatric population is associ-
ated with decreased valve longevity and
frequent need for reoperation due to lack of
growth potential with development of PPM and
most importantly SVD that’s faster than that
seen in adults and inversely related to patient
age and prosthesis size [2,4,16].
Alsoufi et al reported outcomes of 110 children
who’ve undergone 123 AV or MV replacement
with TP or homograft (HG). Among that patient
cohort, 36 patients had AVR including 21 TP and
15 HG. Survival was 85% at 10 years while free-
dom from AV reoperation was about 35% at
10 years and 15% at 15 years with median TP lon-
gevity about 7.5 years. Overall 10-year freedom
from TE and bleeding was 100% while freedom
from endocarditis was 97%. The majority of pa-
tients were in New York Heart Association
(NYHA) functional class I/II. Many females
underwent successful uncomplicated pregnancies
[16]. Those results suggested that while valve
reoperation was inevitable, the lack of other opti-
mal AV substitutes, favorable results such as low
prosthesis-related morbidity rate, good long-term
survival and functional status encourage consider-
ation of TPs as valid replacement alternatives in
selected children; especially teenage females and
those with poor compliance with anticoagulation
medications.Homografts (HG)
HGs come in different ranges, are associated
with excellent hemodynamic profiles that are sim-
ilar for larger and smaller sizes and hence they’re
suitable for the smallest children. Nonetheless,
availability of HG, especially in the smallest
ranges, varies due to the limited donor pool. They
have a negligible TE risk and therefore do not
require anticoagulation. Nonetheless, similar to
TPs, they undergo rapid SVD leading to deteriora-
tion of their hemodynamic properties with
development of obstruction and regurgitation,
decreasing their longevity and requiring reopera-
tion [2,4,16,17]. The fact that HG is resilient to
infection make it the AVR of choice in patients
having invasive endocarditis; however, HG use
in pediatric population for other pathologies is
very limited, especially that reoperations are chal-
lenging and associated with risks of bleeding and
coronary injury. In the series from Riyadh, reoper-
ation need for HG was similar to that of TP in chil-
dren with only about 15% of patients free from AV
reoperation at 10 years. Similarly, survival was
about 83% and freedom from TE, bleeding or
endocarditis was 100% [16].
Ross procedure (Ross)
Ross is an attractive AVR choice in children. It
utilizes the pulmonary autograft (AG) in the aortic
position and therefore it can be applied to all pa-
tients’ ages and is associated with excellent hemo-
dynamic profile and cardiac recovery in all sizes.
The growth potential of AG allows continuation
of their superior hemodynamic profile long after
Ross [18–21].
Furthermore, it’s a versatile operation that can
be applied to patients with various left ventricular
outflow tract (LVOT) and AV pathologies. The
addition of a Konno-type aorto-ventriculoplasty
in conjunction with Ross (Ross–Konno) allows
successful management of patients with signifi-
cant annular hypoplasia and those with complex
multi-level LVOT obstruction [22–25]. The original
Ross–Konno description involved a large incision
in the ‘‘Konno’’ septum creating a ventricular sep-
tal defect (VSD) that was closed with a patch or
anterior wall muscle extension of the harvested
AG [22–25]. The modified Ross–Konno is currently
utilized by many groups and involves an incision
into the aortic annulus below the left/right com-
missure and extensive septal myectomy thus
enlarging the LVOT without a VSD patch use [26].
The AG is implanted most commonly as a full
root in children. Alternatively, the subcoronary
or inclusion techniques could be utilized in older
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young children with small aortic roots [27]. TE risk
following Ross is negligible and therefore antico-
agulation isn’t required [1,2,14,25,28–33].
Survival: Despite technical complexity, Ross has
been shown to be safe in experienced hands. In
the Ross registry and numerous contemporary
series, reported operative mortality is under 2.5%
[1,2,14,25,28–33]. Nonetheless, infants less than
1 year of age continue to have a high mortality risk
approaching 15–20%, as compared to a mortality
risk approaching 1% in children above 1 year of
age [34–37].
Recent series demonstrated several risk factors
for mortality in infants less than 1 year of age.
Woods et al from Milwaukee reported Society of
Thoracic Surgeons Congenital Heart Surgery
Database outcomes of 160 infants who had under-
gone AVR including 145 Ross procedures (Ross–
Konno in 101); overall hospital mortality was 16%
and was 29% for neonates compared to 11% in
older infants. Risk factors included concomitant
arch surgery and post-operative ECMO [34].
Shinkawa et al from Ann Arbor reported 10-year
survival of 77% and freedom from reoperation of
51% in 31 infants who had undergone Ross. Risk
factors for death were concomitant MV and arch
surgery [35]. Hickey et al from Toronto reported
the Congenital Heart Surgeons Society (CHSS) re-
sults of 39 infants who had undergone Ross. They
reported 5-year survival of 44% in neonates and
76% for infants older than 3 months. They noted
several features that were associated with poor
outcomes such as emergency surgery, coexisting
MV pathology and LV dysfunction [36]. Alsoufi
et al from Riyadh examined a similar patient co-
hort of 21 infants who had undergone Ross. Over-
all survival was 81% at 1 month and 63% at
5 years. Factors associated with poor outcomes in-
cluded neonates, concomitant MV surgery, longer
cross clamp time and post-operative ECMO. Of
interest, Ross–Konno and prior surgical interven-
tion weren’t associated with increased mortality
risk. Freedom from reoperation was 86% at 5 years
[37]. Those findings suggested that prior palliation
with surgical or percutaneous aortic valvuloplasty
should be attempted and might be associated with
decreased mortality risk. They also suggested that
outcomes following Ross in infants with complex
LVOT obstruction could improve by better patient
selection with expected long-term survival
approaching 90% in those older than 3 months,
isolated AV pathology not requiring concomitant
MV or aortic arch surgery. Conversely, neonates
with concomitant significant MV pathology oraortic arch obstruction might benefit better from
other surgical alternatives such as the Yasui oper-
ation or even single ventricle palliation [37].
Time-related survival in children following Ross
is stable with very little attrition risk beyond the
perioperative period. Several series demonstrated
that Ross in children offers the best long-term sur-
vival among other AVR substitutes [1,2,14,25,28–
33]. This is mainly attributed to the excellent AG
hemodynamic profile, trivial TE risk and lack of
anticoagulation need.
Fate of the autograft: Despite excellent survival
and superior hemodynamics following Ross, rec-
ommendation for this procedure has been declin-
ing, especially in older children in whom there are
other AVR alternatives. This is mainly due to con-
cerns about the development of neoaortic root
dilatation, with or without subsequent AG regur-
gitation [18–21,32,38–44]. Until now it remains
debatable whether the neoaortic annulus and root
enlargement following Ross is actual growth in a
manner proportional to somatic growth or patho-
logical remodeling with disproportionate and
excessive dilatation [18–21,43,44] it’s also debat-
able whether or not the pulmonary artery or aortic
dimensions should be used as standard measure-
ment reference points [18]. In general, neoaortic
root dimensions immediately after Ross are larger
than in healthy children, the annulus grows in
proportion to somatic growth of the child while
the root at the sinuses level and the sinotubular
junction (STJ) dilates with time. In addition, AG
regurgitation can develop in association with neo-
aortic dilatation, more so with STJ than sinuses
dilatation [18–21,43,44]. The most remarkable
demonstration of the fate of AG in children was
reported by Pasquali et al from Philadelphia; they
showed that at 6 years following Ross, freedom
from neoaortic root Z score >4 was 3% only, free-
dom from AG regurgitation Pmoderate was 60%
and freedom from AG reintervention was 88%
[38].
Several factors were identified to be associated
with requirement for late AG reoperation. Those
factors included STJ dilatation, bicuspid aortic
valve with predominant aortic regurgitation (AI),
dilated aortic annulus and geometric mismatch
between semilunar valves (aortic larger than pul-
monary) [23,32,38–45]. Moreover, older patients
at time of Ross show faster increase in neoaortic
root dimensions and aortic regurgitation [32]. It
could be that AG might better adapt to the higher
pressure in the aorta when it’s transitioned to the
aortic position early at a younger age when
smooth muscle cells are more prone to
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the required structural changes in its wall to with-
stand aortic pressure. Moreover, children under-
going Ross at an early age often have a more
severe multi-level LVOT obstruction with higher
likelihood of having associated pulmonary hyper-
tension. That pulmonary hypertension might have
led to ‘‘priming’’ of the pulmonary root through
structural changes in its wall thus allowing it to
better adapt to the systemic blood pressure once
it was transitioned into the aortic position. Finally,
AG wall in older patients with higher systemic
blood pressure might experience higher wall
stress which could offer a stimulus for adverse
remodeling and dilatation.
Children undergoing Ross–Konno comprise an
interesting group of patients. By definition, those
patients do not have an aortic annulus larger than
the pulmonary valve, and most do not have pri-
marily AI prior to Ross, thus they’re potentially
at a lower risk of developing root dilatation and
AG regurgitation. On the other hand, Ross–Konno
involves incision across the annulus into the sep-
tum and placement of VSD patch with resultant
loss of native annular support to AG and therefore
potentially presents a higher risk of root dilatation
and development of regurgitation. Fadel et al from
Riyadh reported serial echocardiographic follow-
up following modified Ross–Konno without VSD
patch use; they demonstrated that both neoaortic
annulus and root increase in size proportionately
to somatic growth and that only few patients
developed AG regurgitation that was usually mild
and non-progressive with no requirement for AG
reoperation [26].
Several surgeons adopted technical modifica-
tions aiming to reduce late AG dilatation when
it’s implanted as a full root such as thinning of
muscle rim below the valve, suturing AG within
the native aortic annulus, shortening AG, enforc-
ing proximal and distal suture lines with Dacron
felt or replacing the ascending aorta with Dacron
graft [27,32,46]. Reports in the literature suggested
that AG stabilization and root inclusion or subcor-
onary implantation techniques might be associ-
ated with less incidence of AG dilatation and
development of regurgitation [27]. Moreover,
some surgeons suggested wrapping the AG with
an absorbable mesh, glutaraldehyde-fixed bovine
pericardium or encasing it in a Dacron tube to
prevent dilatation [47]. Those techniques are suit-
able only for patients who won’t need AG growth
because the outer shell prohibits this. Further fol-
low-up is required to confirm the hypothetical
advantages of those modifications.In children with CHD, freedom from AG reoper-
ation ranges between 75% and 95% at 10 years
[1,2,14,25.28–33]. In a series by Alsoufi et al from
Riyadh examining outcomes of 151 patients fol-
lowing Ross for CHD, 10-year survival was 92%,
freedom from AG and right ventricle to pulmon-
ary artery (RVPA) conduit reoperation was 95%
and 71%, respectively [29]. In another series by
the same group examining outcomes of 227 chil-
dren following Ross for various etiologies, 10-year
freedom from AG reoperation for patients with
preoperative AS, AI and mixed disease was 97%,
69% and 93%, respectively. Risk factors for in-
creased risk of AG reoperation were RF and ear-
lier year of surgery. They demonstrated that AG
longevity could be improved with better patient
selection with excepted freedom from reoperation
in younger patients with predominant AS exceed-
ing 95% compared to less than 50% in older pa-
tients with risk factors such as RF, AI and dilated
aortic annulus [32].
Several series showed high failure and reopera-
tion rates in children with RF undergoing Ross. In
a recent study from Riyadh reporting outcomes of
104 children with RF who’ve undergone Ross; at
10 years, freedom from AG regurgitationPmod-
erate was 63%, freedom from AG reoperation
was 65% for AI versus 90% for AS/mixed disease,
freedom from RVPA conduit was 83% and from
any cardiac reoperation was 53%. The majority of
failures were evident in the first few years after
Ross and the predominant pathology requiring
AG reoperation was annular dilatation with cusp
prolapse and failure of coaptation in 16/27, recur-
rence of inflammatory valvulopathy similar to that
in RF in 8/27 reoperations. Patients with predom-
inant preoperative AI, those with dilated annulus
and concomitant MV regurgitation were at higher
risk of HG failure. Those findings suggested that
Ross should be used only selectively in children
with RF with potential candidates being those
with predominant AS, no dilated annulus, no
associated MV disease and no active inflammatory
markers [1,32,48].
Management of the failing AG depends on the
mode of failure, status of the cusps and size of
the neoaortic root. Patients with reasonably pre-
served AG cusps and regurgitation due to root
dilatation and poor coaptation are candidates for
AV sparing root replacement. In the past decade,
there have been few series reporting successful
reoperation on failing AG using the reimplanta-
tion or remodeling AV preservation techniques
with good early outcomes [49,50]. Those tech-
niques increase AG longevity despite the need
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tients in whom AG valve is irreparable due to
recurrent inflammation, endocarditis, or extensive
cusp thinning and destruction, autograft valve
replacement (AGVR) is required. Choices for
AGVR include redo root replacement (ARR) with
a Bentall operation or AGVR with stented pros-
thesis (SP) that’s placed within the neoaortic root.
Redo ARR is complex, associated with important
risk of bleeding and coronary injury and could
add significant risk, especially if concomitant car-
diac surgery is needed at time of reoperation
[51–53]. On the other hand, AGVR with SP placed
within the neoaortic root is simpler and associated
with lower risk of bleeding or coronary injury.
Nevertheless, AGVR with SP would leave the neo-
aortic root behind with concerns of continued
dilatation, aneurysm formation and requirement
for subsequent root reoperation. In a series from
Riyadh examining the fate of the remaining neo-
aortic root following AGVR with SP in 50 patients,
there were no operative deaths and 10 years sur-
vival was 95%. Freedom from prosthesis, root
and all-cause reoperations was 97%, 98% and
90% at 10 years, respectively. Serial echocardio-
graphic data showed that there was little but pro-
gressive increase of remaining root and ascending
aorta diameters however the requirement root
reinterventions were very rare [54]. Those findings
suggest that AGVR with SP is justified as it’s asso-
ciated with low operative risk and good late out-
comes and that redo ARR should be reserved
with patients with significant root dilatation
>4 cm at time of AG reoperation. Patients under-
going AGVR with SP should be followed for pro-
gressive root dilatation. Although published
reports of AG dissection or rupture are rare, the
incidence of those complications is likely to
increase.
Fate of RVPA conduit: Reoperation for RVPA con-
duit change is a continuous problem following
Ross. Longevity of RVPA conduit in patients fol-
lowing Ross is thought to be higher than that
placed following repair of other congenital anom-
alies due to several factors such as the anatomic
position of the conduit and the infrequent inci-
dence of branch pulmonary stenosis. Several fac-
tors have been identified to be associated with
RVPA conduit reoperation. Those included smal-
ler conduit size, fresh homografts, aortic homo-
grafts and longer follow-up. In a meta-analysis
by Takkenberg et al from Rotterdam, The average
incidence of structural and non-structural degen-
eration of RVPA conduit in children was 1.6 (range
0.7–4.9) per 100 patient-years [31]. Reportedfreedom from RVPA conduit reoperation was 90–
95% at 10 years and 75–85% at 15 years
[1,2,14,25.28–33]. Decellularization of homografts
was introduced in the early 2000’s and this process
removed the endothelial cells and most of the
other viable cells in the interstitial matrix without
weakening the tissue. Initial experience suggests
that those conduits have superior longevity com-
pared to cryo-preserved ones and might further
decrease reoperation rate.
In experienced hands RVPA conduit change is a
relatively simple procedure and has been associ-
ated with low morbidity and operative mortality.
RVPA conduit replacement will likely continue
to be the most common type of reoperation fol-
lowing Ross. However, it’s important also to note
recent advances in percutaneous pulmonary valve
replacement that have allowed cardiologists to ad-
dress this problem without surgical intervention.
The immediate and short-term results of percuta-
neous pulmonary valve implantation are encour-
aging however longer follow-up is needed [55].
Cardiac reoperation: The initial thoughts were
that reoperations following Ross would be limited
to RVPA conduit change. Nonetheless, increased
follow-up showed that reoperation was not as
infrequent as anticipated and often involved mul-
tiple valves in addition to the coronaries and
ascending aorta. Those reoperations could be spe-
cifically related to Ross, for example AG, RVPA
conduit and coronary reoperations; or could be
unrelated to Ross but rather to underlying cardiac
pathology, for example MV and tricuspid valve
reoperations. Ross is a complex operation and car-
diac reoperations following Ross can be often
more complicated [52,53,56]. A recent review from
the Mayo clinic reported that 144 procedures were
performed in 56 patients who required cardiac
reoperations following Ross. Despite low hospital
mortality (1 patient), surgical morbidity was high
and results were beset by 4 additional deaths at
a median follow-up of 8 months [52]. In a review
from Riyadh, 50 patients underwent cardiac reo-
perations following Ross done in childhood. Risk
factors for cardiac reoperation were RF, AI, con-
comitant cardiac surgery, use of fresh homografts
and earlier era of surgery. Overall, 32 (55%) reo-
perations were isolated procedures whereas 26
(45%) were more complex involving 2–4 simulta-
neous cardiac procedures. In total, 92 procedures
were performed including AVR (n = 31), RVPA
conduit change (n = 23), MV replacement (n = 18),
MV repair (n = 11), tricuspid valve repair (n = 5)
and other (n = 4). There was 1 operative and 1 late
death. Survival was 98% at 10 years. During
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surgery following initial reoperation with freedom
from additional cardiac surgery of 82% at 10 years
[56]. That study demonstrated that despite com-
plexity, Ross reoperation can be performed in
experienced centers with low mortality and good
mid-term results.
Double valve replacement
Several cardiac disorders, such as RF, endocar-
ditis and CHD, can affect multiple valves and
necessitate simultaneous double or triple valve
surgery. Double valve surgery is challenging, of-
ten complicated and prolonged due to previous
surgeries and common requirement for concomi-
tant procedures such as reconstruction of valve
annuli or the base of the heart secondary to infec-
tion, calcification, fibrosis, or insufficient space to
secure the placement of prostheses of adequate
size. Moreover, early post-operative care of those
patients is often difficult due to the frequent pres-
ence of poor preoperative clinical and hemody-
namic status that might further imperil outcome.
Only few series in the literature describe out-
comes following simultaneous AV and MV
replacement in children. In a recent study from
Riyadh reporting outcomes following double
valve replacement in 84 children; operative mor-
tality was 4%, 15-year survival was 78% (92% for
TP and 76% for MP) while 15-year freedom from
reoperation was 59% (70% for MP and 0% for
TP). Freedom rates from endocarditis, TE and
bleeding complications at 15 years were 90%,
92%, and 96%, respectively. Among survivors,
95% were in NYHA class I/II. Those findings indi-
cated that while reoperation risk was higher, free-
dom from other valve related complications was
similar to that in patients who’ve undergone
single valve replacement of the same type [57].
Comparisons of different aortic valve alternatives
Few studies in the literature compared out-
comes of various AVR options in children. Karam-
lou et al from Toronto reported results following
AVR with several alternatives in 160 patients; on
multi-variable analysis, Ross was associated with
improved survival while HG or TP use was associ-
ated with increased reoperation [2]. Ruzmetov
et al. from Indianapolis compared outcomes
following AVR with several alternatives in 147
patients; they found that 10-year survival was
highest following Ross (98%) as compared to MP
(88%), HG (87%) or TP (82%) while freedom from
reoperation was highest following Ross (91%) as
compared to MP (88%), HG (87%) and TP (40%)[14]. Alsoufi et al from Riyadh compared outcomes
in 346 children following AVR (215 Ross and 131
MP). After propensity adjustment, MP use was a
risk factor for early and late death while Ross
was a risk factor for reoperation; however they
had a large proportion of children with RF to ac-
count for the increased reoperation rate after Ross
[1]. Lupinetti et al from Seattle compared out-
comes following 51 AVR in children (26 MP, 19
Ross, 6 HG); they found lower 2-year freedom
from reoperation in MP group (80%) as compared
to Ross and HG (96%) [58]. In another study, the
same group compared outcomes between chil-
dren undergoing AVR with Ross (n = 78) or HG
(n = 25); they found equal 7-year survival for both
groups (96%) but superior freedom from reopera-
tion for Ross (88%) vs. HG (73%); and also demon-
strated that Ross was associated with superior
maintainable hemodynamics over HG that
showed deterioration of hemodynamic profile in
conjunction with SVD [17].Summary and recommendations
In summary, AVR in children creates a lifelong
disease that continues throughout adulthood.
Each AV substitute has recognized shortcomings
that affect late survival and reoperation need.
The choice of AV substitute should be carefully
deliberated at time of first AV intervention taking
into consideration each patient’s unique
anatomic, clinical and social characteristics, and
acknowledging the fact that many selected
management plans would require eminent reop-
eration necessitating lifetime observation.
In children with AV disease requiring operation,
AV repair should be attempted as a temporizing
or lasting initial treatment as it improves symp-
toms, stabilizes the heart and allows delay in
AVR need till an older age when surgery is associ-
ated with lower risk and different replacement
options can be offered. AVR is necessary in
patients in whom AV could not be repaired or
those following repair failure. Neonates, infants
and small children with AS requiring AVR should
undergo Ross or Ross–Konno. Although Ross is
associated with clear survival advantage over
other AVR alternatives in that patient population,
operative mortality for Ross is the highest in that
subgroup of patients, especially if concomitant
MV or arch surgery is required. Selected neonates
and small infants with significant coexisting MV
and arch anomalies should be considered for
alternative management strategies that could
include single ventricle palliation. In older
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2014;26:33–41children, Ross continues to offer survival and
reoperation advantage over other alternatives in
patients with AS or mixed disease after a prior
palliation. Nonetheless, AVR with MP might be a
superior choice in patients with predominant AI
and dilated AV annulus. AVR with TP could also
be considered in that setting especially in females
and children incompliant with anticoagulation
regimen. HG use is reserved for infants and small
children in whom the pulmonary AG could not be
used or in cases with invasive endocarditis. In
children with RF, AVR with MP or TP should be
contemplated while Ross should be offered only
in a selected group of patients with no active
inflammation, no AI, no dilated AV annulus, and
no concomitant involvement of other cardiac
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